

10/585892
LAPG Rec'd PCT/PTO 11 JUL 2006

Express Mail Label No. EV 682 424 416 US Dated: July 11, 2006

Docket No.: PLI-001US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jerzy Gebicki *et al.*

Application No.: National Phase of
PCT/EP2005/050057

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: THE USE OF QUATERNARY PYRIDINIUM
SALTS AS VASOPROTECTIVE AGENTS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Applicants have not submitted English translations for B1 and C7 in accordance with MPEP section 609.4(a)(III) Applicants submit herewith a copy of the International Search Report for Application No. PCT/EP2005/050057, dated September 30, 2005, which indicates the degree of relevance found by the foreign office.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. PLI-001US. A duplicate copy of this paper is enclosed.

Dated: July 11, 2006

GAD/BCT/mch

Respectfully submitted,

By

Giulio A. DeConti, Jr.

Registration No.: 31,503

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	Not Yet Assigned 85892
				Filing Date	Concurrently Herewith
				First Named Inventor	Jerzy GEBICKI
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	PLI-001US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number-Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	DE-840698	07-05-1952	Cilag Aktiengesellschaft, Schaffhausen (Schweiz)		
	B2	WO-00/40559-A1	07-13-2000	Technical University of Lodz		
	B3	WO-2005/067927-A2	07-28-2005	Pharmena Sp zo.o.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Filetti, S. et al, "Insulin Receptor Down-Regulation: Prevention at a Post-Receptor Site," <i>Endocrinology</i> , Vol. 108(6):2409-2411 (1981)	
	C2	Fischer, L.J. et al, "Characteristics of Nicotinamide and N ¹ -Methylnicotinamide Protection from Alloxan Diabetes in Mice," <i>Toxicology and Applied Pharmacology</i> , Vol. 70:148-155 (1983)	
	C3	Fukushima, Tetsuhito et al, "Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson's disease," <i>Exp. Toxic Pathol.</i> , Vol. 53:469-473 (2002)	
	C4	Fukushima, T. et al, "Radical Formation Site of Cerebral Complex I and Parkinson's Disease," <i>Journal of Neuroscience Research</i> , Vol. 42:385-390 (1995)	
	C5	Gebicki, Jerzy et al, "1-Methylnicotinamide: A Potent Anti-Inflammatory Agent of Vitamin Origin," <i>Polish Journal of Pharmacology</i> , Vol. 55:109-112 (2003)	
	C6	Lea, Michael A. et al, "Effects of Nicotinamide and Structural Analogs on DNA Synthesis and Cellular Replication of Rat Hepatoma Cells," <i>Cancer Biochem. Biophys.</i> , Vol. 7:195-202 (1984)	
	C7	Taguchi, Hiroshi, "Vitamins and apoptosis - Induction of apoptosis in human cancer cells by nicotinic acid-related compounds," <i>Nippon Rinsho.</i> , Vol. 57(10):2319-2324 (1999)	
	C8	International Search Report for Application No. PCT/EP2005/050057, dated September 30, 2005	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--